CSBio CSBio

X
[{"orgOrder":0,"company":"Medicure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medicure Announces AGGRASTAT\u00ae Shows Promise in Treating Thrombotic Complications Due to COVID-19 in Early Clinical Reports","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Medicure"},{"orgOrder":0,"company":"SMITH & NEPHEW INC","sponsor":"Healiva","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Healiva Acquires Two Wound-healing Cell Therapy Assets From Smith+Nephew","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Cell and Gene therapy","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"SMITH & NEPHEW INC"},{"orgOrder":0,"company":"Hemostemix","sponsor":"McGill University Health Centre","pharmaFlowCategory":"D","amount":"$0.2 million","upfrontCash":"Undisclosed","newsHeadline":"InvestmentPitch Media Video Discusses Hemostemix and its $250,000 in Funding from McGill University Health Centre Foundation for Clinical Trial of ACP-01","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Hemostemix"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            The funding will be used to complete a phase II double blind randomized clinical trial of ACP-01, an autologous angiogenic cell precursor, as a treatment of ischemic cardiomyopathy at the McGill University Health Centre.

            Lead Product(s): ACP-01

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: ACP-01

            Highest Development Status: Phase II Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: McGill University Health Centre

            Deal Size: $0.2 million Upfront Cash: Undisclosed

            Deal Type: Funding January 23, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The first asset, EpiDex®, is an autologous epidermal equivalent that provides a surgery-free approach to healing chronic venous leg ulcers (VLUs). The second asset, now named healiva®002, is an off-the-shelf allogeneic cell therapy.

            Lead Product(s): Tissue-engineered Autologous Outer Root Sheath Keratinocytes

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Epidex

            Highest Development Status: Phase II Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Healiva

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition June 01, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Notably, a non-randomized, case-controlled, investigator sponsored proof of concept study evaluating AGGRASTAT® in combination with standard of care in patients with severe COVID-19 and hypercoagulability found that enhanced platelet inhibition improves hypoxemia.

            Lead Product(s): Tirofiban,Clopidogrel,Aspirin

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Aggrastat

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 24, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY